Aortic Aneurysm Market By Type (Abdominal Aortic Aneurysm (AAA); Thoracic Aortic Aneurysm (TAA)); By Product Type (Stent Grafts; Catheters; Synthetic Grafts); By Treatment Type (Endovascular Aneurysm Repair (EVAR); Open Surgical Repair (OSR)); By End-User (Hospitals; Ambulatory Surgical Centers (ASCs); Specialty Cardiac Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

Aortic Aneurysm Market Size & Overview

The global aortic aneurysm market was valued at $4.3 billion in 2023 and is projected to reach around $7.4 billion by 2030, growing at a CAGR of 7.8% from 2024 to 2030, driven by the increasing prevalence of cardiovascular diseases, aging populations, and advancements in endovascular repair technologies.

 

The rising adoption of minimally invasive endovascular aneurysm repair (EVAR) & thoracic endovascular aneurysm repair (TEVAR) procedures is significantly reducing surgical risks and hospital stays, contributing to market expansion. Additionally, the increasing use of biodegradable stent grafts, AI-driven imaging for early detection & personalized treatment approaches is expected to fuel innovation. However, factors such as the high cost of procedures, limited awareness in developing regions, and complications associated with open surgical repair may pose challenges. North America currently dominates the market due to advanced healthcare infrastructure, strong reimbursement policies, and a high incidence of abdominal & thoracic aortic aneurysms, while Asia-Pacific is expected to witness the fastest growth due to improving healthcare access & increasing awareness of early diagnosis.

 

Aortic Aneurysm Market Dynamics:

Market Drivers

Rising Prevalence of Aortic Aneurysms

The growing incidence of aortic aneurysms, particularly abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA), is a significant driver of market growth. According to the CDC, approximately 200,000 people in the U.S. are diagnosed with an aortic aneurysm each year. Aortic aneurysms are estimated to lead to 150,000 ~ 200,000 deaths per year worldwide.  Factors such as aging populations, hypertension, and smoking habits contribute to the increasing prevalence, fueling the demand for early diagnosis and treatment solutions such as endovascular aneurysm repair (EVAR) and open surgical repair (OSR).

Advancements in Endovascular Repair Technologies

Technological advancements in minimally invasive procedures, particularly in stent grafts and catheter-based interventions, are driving market expansion. The shift toward endovascular aneurysm repair (EVAR), which has a lower complication rate (20% less) compared to open surgery, is increasing patient preference for these procedures. Companies like Medtronic & Cook Medical are investing heavily in next-generation stent grafts with improved flexibility & durability, enhancing treatment outcomes and expanding the market.

 

Market Opportunities

Growing Demand for Personalized & AI-Driven Aneurysm Monitoring

The integration of artificial intelligence (AI) & imaging analytics in aneurysm detection & monitoring presents a substantial growth opportunity. AI-powered diagnostic tools can predict aneurysm growth & rupture risks with high accuracy, allowing for early intervention. Companies such as Siemens Healthineers & GE Healthcare are leveraging AI-based imaging software to improve aneurysm diagnosis rates, opening new revenue streams in the market.

Expanding Healthcare Infrastructure in Emerging Markets

The increasing investment in healthcare infrastructure in regions such as Asia-Pacific & Latin America is creating opportunities for market expansion. Countries like China & India are witnessing a 20-30% annual increase in vascular surgical procedures, driven by improved access to healthcare, rising awareness & government initiatives for cardiovascular disease management. This growth opens doors for international medical device manufacturers to expand their footprint in these high-growth regions.

 

Market Challenges

High Cost of Aneurysm Treatment and Devices

The cost of aortic aneurysm treatment, particularly for advanced stent grafts & surgical interventions, is a major limiting factor in market growth. The average cost of EVAR procedures can range between $25,000 - $50,000 per patient, making it unaffordable for many, especially in low-income regions. Despite reimbursement policies in developed nations, the high cost of treatment remains a barrier to widespread adoption.

Complications and Post-Surgical Risks

Although minimally invasive procedures have reduced the risk profile of aortic aneurysm treatment, complications such as endoleaks, graft migration & aneurysm rupture still pose challenges. Studies indicate that around 10-15% of EVAR patients experience endoleaks, requiring secondary interventions, which increases healthcare costs & risks for patients. This concern often limits the adoption of endovascular repair techniques, particularly among elderly and high-risk patients.

 

Aortic Aneurysm Market Segmentation: A Comprehensive Overview

By Type:

• Abdominal Aortic Aneurysm (AAA)

• Thoracic Aortic Aneurysm (TAA)

 

By Product Type:

• Stent Grafts

• Catheters

• Synthetic Grafts

 

By Treatment Type:

• Endovascular Aneurysm Repair (EVAR)

• Open Surgical Repair (OSR)

 

By End-User:

• Hospitals

• Ambulatory Surgical Centers (ASCs)

• Specialty Cardiac Centers

 

By Region:

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Aortic Aneurysm Market Segment Analysis:

By Type:

Leading Segment: Abdominal Aortic Aneurysm (AAA)

Abdominal Aortic Aneurysm (AAA) is the leading segment in the aortic aneurysm market, holding the largest market share. It accounts for approximately 70-80% of all diagnosed aortic aneurysms. AAA is a condition where there is an enlargement of the abdominal aorta, often leading to life-threatening complications if untreated. The aging population, along with increased awareness & diagnostic advancements, has driven significant demand for AAA treatment options. AAA is more common among individuals with hypertension, smoking history & genetic predisposition, contributing to its dominance in the market. With technological advancements in endovascular repair (EVAR) & stent grafts, AAA remains the primary focus in the aortic aneurysm treatment landscape.

Fastest-Growing Segment: Thoracic Aortic Aneurysm (TAA)

Thoracic Aortic Aneurysm (TAA) is the fastest-growing segment in the aortic aneurysm market, with a CAGR of approximately 7-8% over the forecast period. This growth is primarily driven by improved diagnostic techniques, such as high-resolution imaging & CT scans, which allow for early detection and treatment of TAA. As the global incidence of TAA rises due to factors such as aging populations & lifestyle changes, including hypertension and high cholesterol levels, the demand for treatments for TAA is expected to continue growing. This segment is anticipated to grow faster than AAA due to the increasing number of patients diagnosed with TAA who require specialized treatment options.

 

By Product Type:

Leading Segment: Stent Grafts

Stent grafts dominate the product type segment of the aortic aneurysm market, holding the largest share, approximately 60-65%. Stent grafts are used to support the aorta during aneurysm repair, making them essential in both open surgical repair (OSR) & endovascular aneurysm repair (EVAR). The use of stent grafts, particularly in EVAR, has significantly increased due to their minimally invasive nature, offering faster recovery & fewer complications compared to traditional open surgery. The global preference for stent grafts is driven by their ability to effectively treat both AAA and TAA with high success rates.

Fastest-Growing Segment: Synthetic Grafts

Synthetic grafts are the fastest-growing segment in the product type category, with a projected CAGR of 9-10%. The increasing adoption of synthetic grafts is due to their durability, reduced risk of infection & improved performance over traditional graft materials. Synthetic grafts are primarily used in open surgical repair (OSR) and are becoming more popular as surgical techniques continue to evolve. The growth of this segment is largely driven by their ability to provide long-lasting solutions for aortic aneurysm repairs & their growing use in both elective and emergency surgeries.

 

By Treatment Type:

Leading Segment: Endovascular Aneurysm Repair (EVAR)

Endovascular Aneurysm Repair (EVAR) holds the largest share in the treatment type segment, accounting for around 60% of the market. The popularity of EVAR has been rapidly increasing because it offers a minimally invasive treatment for aortic aneurysms, which significantly reduces patient recovery times & lowers the risk of complications compared to open surgical repair (OSR). The increasing number of patients opting for EVAR, driven by its less invasive nature & high success rates, is a key factor for the dominance of this treatment method.

Fastest-Growing Segment: Open Surgical Repair (OSR)

Although EVAR is the leading treatment, Open Surgical Repair (OSR) is the fastest-growing segment, with a projected CAGR of 5-6%. OSR remains a necessary treatment for large or complex aneurysms that cannot be addressed by EVAR. Despite the trend toward less invasive techniques, OSR is still crucial in certain cases, and its growth is supported by advancements in surgical techniques, post-operative care, and a rising number of patients with advanced-stage aneurysms requiring traditional surgery.

 

By End-User:

Leading Segment: Hospitals

Hospitals remain the leading end-user in the aortic aneurysm market, accounting for the majority of market share at approximately 70%. Hospitals are the primary setting for both EVAR & OSR procedures due to their ability to offer a wide range of surgical treatments & post-operative care. With access to advanced medical technologies, trained specialists, & comprehensive diagnostic tools, hospitals continue to be the go-to destination for patients with aortic aneurysms. The rise in hospital-based diagnostic and treatment procedures is expected to continue, maintaining hospitals' dominant position in the end-user sector.

Fastest-Growing Segment: Ambulatory Surgical Centers (ASCs)

Ambulatory Surgical Centers (ASCs) are the fastest-growing end-user segment in the aortic aneurysm market, with a CAGR of around 8%. The increasing demand for minimally invasive procedures like EVAR, which require shorter recovery times, has driven the growth of ASCs. These centers are becoming increasingly popular as patients seek outpatient surgical options, enabling them to return to normal activities faster. ASCs benefit from lower overhead costs & shorter waiting times, making them an attractive alternative to traditional hospital settings for aortic aneurysm repairs.

 

By Region:

Leading Region: North America

North America holds the largest market share in the aortic aneurysm market, accounting for approximately 40-45% of the global market. The US, in particular, is a key player, with high healthcare spending, advanced medical technologies, and a large patient population. The market's dominance in this region is attributed to a high prevalence of risk factors such as smoking, hypertension & obesity, contributing to the rise in aortic aneurysm cases. The region's strong healthcare infrastructure & adoption of innovative treatments like EVAR further bolster its position.

Fastest-Growing Region: Asia-Pacific

The APAC region is the fastest-growing market for aortic aneurysm treatments, with a projected CAGR of 8-9%. The rapid growth in countries like China & India, where the aging population & increasing urbanization are contributing to a rise in cardiovascular diseases, is fueling the market's expansion. APAC countries are also investing heavily in healthcare infrastructure and access to advanced medical treatments, increasing the adoption of both open surgical repair (OSR) and endovascular aneurysm repair (EVAR) procedures. As healthcare awareness and affordability improve, the aortic aneurysm market in the region is expected to experience significant growth.

 

Aortic Aneurysm Market Report Coverage

Report Attribute	Details
Forecast Period	2023 – 2030
Market Size Value in 2023	USD 4.3 Billion
Revenue Forecast in 2030	USD 7.4 Billion
Overall Growth Rate	CAGR of 7.8% (2023 – 2030)
Base Year for Estimation	2022
Historical Data	2017 – 2021
Unit	USD Million, CAGR (2023 – 2030)
Segmentation	By Type, By Product Type, By Treatment Type, By End-User, By Geography
By Type	Abdominal Aortic Aneurysm (AAA); Thoracic Aortic Aneurysm (TAA)
By Product Type	Stent Grafts; Catheters; Synthetic Grafts
By Treatment Type	Endovascular Aneurysm Repair (EVAR); Open Surgical Repair (OSR)
By End-User	Hospitals; Ambulatory Surgical Centers (ASCs); Specialty Cardiac Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	US, Canada, Germany, China, India, etc.
Market Drivers	Rising prevalence of aortic aneurysms, increasing adoption of minimally invasive surgeries, advancements in endovascular repair technologies
Pricing and Purchase Options	Customized options available

 

Key Players in the Aortic Aneurysm Market

• Medtronic plc

• L. Gore & Associates, Inc.

• Cook Medical Inc.

• Cardinal Health Inc.

• Terumo Corporation

• Lombard Medical, Inc.

• AbbVie Inc.

• Merck & Co., Inc.

• Cardiatis S.A.

• Boston Scientific Corporation

 

Recent Developments

• On January 25, 2024 W. L. Gore & Associates received FDA approval for the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE), the first off-the-shelf endovascular solution for treating complex aneurysms involving the visceral aorta. TAMBE is designed for patients with thoracoabdominal aortic aneurysms (TAAA) and high-surgical-risk patients with pararenal aortic aneurysms (PAAA), offering a minimally invasive alternative to open surgical repair.

• In January 2024, Nectero Medical commenced a Phase II/III clinical trial evaluating the safety & efficacy of its endovascular aneurysm stabilization treatment, Nectero EAST®. This single-use, endovascular system comprises a dual-balloon delivery catheter and a stabilizer mixture of pentagalloyl glucose (PGG), aiming to strengthen the aortic wall and potentially inhibit the progression of abdominal aortic aneurysms (AAA).

• Cardiatis S.A. has introduced the Bifurcated Multilayer Flow Modulator (MFM®), an innovative device designed to treat complex aortic aneurysms. The MFM® technology aims to regulate blood flow within the aneurysm, promoting thrombosis and stabilization of the aneurysmal sac while preserving blood flow to vital branches

 

Future Outlook

The global aortic aneurysm market is poised for steady growth in the coming years, driven by advancements in minimally invasive procedures, increasing adoption of endovascular aneurysm repair (EVAR), and a rising geriatric population prone to cardiovascular disorders. The growing prevalence of aortic aneurysms, especially abdominal & thoracic types, coupled with improved screening programs, is expected to fuel market expansion. Innovations in stent graft technology, including next-generation fenestrated and branched grafts, are enhancing procedural success rates and expanding treatment options for complex aneurysms. Moreover, AI-driven diagnostics & 3D printing technologies are revolutionizing preoperative planning & patient-specific graft design, ensuring better outcomes. However, challenges such as the high cost of procedures, reimbursement limitations & post-surgical complications may restrain market growth, particularly in developing regions. Despite these barriers, ongoing research, strategic collaborations among key players, and increasing healthcare investments are expected to accelerate market expansion, with North America and Europe leading, while Asia-Pacific emerges as a high-growth region due to improving healthcare infrastructure & increasing awareness.